Arbutus Secures Up to $2.25 Billion from Moderna Patent Settlement, Plans Shareholder Capital Return
ABUS sits 57% above its 52-week low of $2.705.
Summary
Arbutus Biopharma has reached a major patent settlement with Moderna for up to $2.25 billion, significantly boosting its financial position and leading to a planned return of capital to shareholders. The company also continues its patent litigation against Pfizer/BioNTech with a favorable ruling.
Key Events · Financing and Capital Events · ABUS
-
Moderna Patent Litigation Settlement
Arbutus and Genevant will receive an aggregate noncontingent lump sum payment of $950 million by July 8, 2026, with Arbutus entitled to 20% after litigation costs, plus its 16% equity ownership in Genevant. An additional contingent payment of up to $1.3 billion is possible based on a favorable ruling in the Moderna §1498 Appeal.
-
Potential Shareholder Capital Return
The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026, following the receipt of its portion of the noncontingent settlement payment.
-
Ongoing Pfizer/BioNTech Patent Litigation
The patent infringement lawsuit against Pfizer/BioNTech is ongoing, with a favorable claim construction ruling issued in September 2025, and further scheduling awaited.
-
Strategic Restructuring and Cost Reduction
During 2024 and 2025, Arbutus implemented significant workforce reductions and ceased discovery efforts, resulting in $12.9 million in restructuring charges in 2025 and a substantial reduction in net cash burn.
Analysis · ABUS · Life Sciences
Arbutus Biopharma has announced a transformative settlement with Moderna, Inc. and its affiliates, resolving all patent infringement litigation. This agreement includes a substantial noncontingent lump sum payment of $950 million (aggregate to Arbutus and Genevant) due by July 8, 2026, with Arbutus directly entitled to 20% of this amount after litigation costs, in addition to its 16% equity stake in Genevant. Furthermore, a contingent payment of up to $1.3 billion is possible based on the outcome of a limited appeal. This significant financial influx, representing a substantial portion of the company's market capitalization, is expected to dramatically improve Arbutus's liquidity and financial runway. The company is actively evaluating a return of capital to shareholders in Q3 2026, signaling a direct benefit to investors. Concurrently, Arbutus continues its patent infringement lawsuit against Pfizer/BioNTech, which saw a favorable claim construction ruling in September 2025, indicating further potential upside. These developments, alongside a strategic restructuring that reduced cash burn, position Arbutus with enhanced financial flexibility and a clearer path forward for its clinical programs, despite an FDA clinical hold on its AB-101 program in the U.S.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $4.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $815.5M. The 52-week trading range was $2.71 to $5.10. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.